ELISA Kit for Cross Linked C-Telopeptide Of Type I Collagen (CTXI)

39.06-10, 000pg/mL

The minimum detectable dose of this kit is typically less than 14.73pg/mL

2h

This assay has high sensitivity and excellent specificity for detection of Cross Linked C-Telopeptide Of Type I Collagen (CTXI).
No significant cross-reactivity or interference between Cross Linked C-Telopeptide Of Type I Collagen (CTXI) and analogues was observed.

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

This assay employs the competitive inhibition enzyme immunoassay technique. A monoclonal antibody specific to Cross Linked C-Telopeptide Of Type I Collagen (CTXI) has been pre-coated onto a microplate. A competitive inhibition reaction is launched between biotin labeled Cross Linked C-Telopeptide Of Type I Collagen (CTXI) and unlabeled Cross Linked C-Telopeptide Of Type I Collagen (CTXI) (Standards or samples) with the pre-coated antibody specific to Cross Linked C-Telopeptide Of Type I Collagen (CTXI). After incubation the unbound conjugate is washed off. Next, avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. The amount of bound HRP conjugate is reverse proportional to the concentration of Cross Linked C-Telopeptide Of Type I Collagen (CTXI) in the sample. After addition of the substrate solution, the intensity of color developed is reverse proportional to the concentration of Cross Linked C-Telopeptide Of Type I Collagen (CTXI) in the sample.

Atp6v0d2 Is an Essential Component of the Osteoclast-Specific Proton Pump That Mediates Extracellular Acidification in Bone Resorption; Borage and fish oils lifelong supplementation decreases inflammation and improves bone health in a murine model of senile osteoporosis; TRAF family member-associated NF-κB activator (TANK) is a negative regulator of osteoclastogenesis and bone formation; Oxytocin Reverses Ovariectomy-Induced Osteopenia and Body Fat Gain; XPO1/CRM1-Selective Inhibitors of Nuclear Export(SINE) reduce tumor spreading and improveoverall survival in preclinical models of prostatecancer (PCa); 5-azacytidine-induced protein 2 (AZI2) regulates bone mass by fine-tuning osteoclast survival; Mutation in Osteoactivin Promotes RANKL-Mediated Osteoclast Differentiation and Survival, but Inhibits Osteoclast Function; Oxytocin reverses osteoporosis in a sex-dependent manner; Lanthanum Chloride Attenuates Osteoclast Formation and Function Via the DownreCavia (Guinea pig )lation of Rankl-Induced Nf-κb and Nfatc1 Activities; N-Homocysteinylation impairs collagen cross-linking in cystathionine β-synthase-deficient mice: a novel mechanism of connective tissue abnormalities.; Reduced femoral bone mass in both diet-induced and genetic hyperlipidemia mice; A novel osteoporosis model with ascorbic acid deficiency in Akr1A1 gene knockout mice.; Optimization of the Time Window of Interest in Ovariectomized Imprinting Control Region Mice for Antiosteoporosis Research; TSC1 regulates osteoclast podosome organization and bone resorption through mTORC1 and Rac1/Cdc42; Combination therapy with BMP‑2 and psoralen enhances fracture healing in ovariectomized mice; Dual PI3 K/mTOR inhibition reduces prostate cancer bone engraftment altering tumor-induced bone remodeling; Transcriptome analysis of osteoblasts in an ovariectomized mouse model in response to physical exercise; Significance of the Tks4 scaffold protein in bone tissue homeostasis; Osteocyte TSC1 promotes sclerostin secretion to restrain osteogenesis in mice;